Log in

Neurocrine Biosciences News Headlines (NASDAQ:NBIX)

$104.67
-1.66 (-1.56 %)
(As of 01/20/2020 03:21 AM ET)
Today's Range
$104.20
Now: $104.67
$107.30
50-Day Range
$103.07
MA: $110.88
$118.57
52-Week Range
$71.85
Now: $104.67
$119.65
Volume743,470 shs
Average Volume736,480 shs
Market Capitalization$9.64 billion
P/E Ratio615.71
Dividend YieldN/A
Beta1.21

Headlines

Neurocrine Biosciences (NASDAQ NBIX) News Headlines

Source:
DateHeadline
Morgan Stanley Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $121.00Morgan Stanley Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $121.00
www.americanbankingnews.com - January 17 at 10:53 AM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Forecasted to Earn FY2020 Earnings of $3.87 Per ShareNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Forecasted to Earn FY2020 Earnings of $3.87 Per Share
www.americanbankingnews.com - January 15 at 6:46 AM
Short Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Declines By 8.4%Short Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Declines By 8.4%
www.americanbankingnews.com - January 14 at 4:34 PM
Neurocrine Biosciences (NBIX) Presents At 38th Annual J.P. Morgan Healthcare Conference - SlideshowNeurocrine Biosciences (NBIX) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 14 at 4:05 PM
Oppenheimer Analysts Raise Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Oppenheimer Analysts Raise Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
www.americanbankingnews.com - January 14 at 6:02 AM
Neurocrine Biosciences (NASDAQ:NBIX) Given New $132.00 Price Target at OppenheimerNeurocrine Biosciences (NASDAQ:NBIX) Given New $132.00 Price Target at Oppenheimer
www.americanbankingnews.com - January 13 at 11:08 AM
Neurocrine Bio expects $238M in Q4 Ingrezza salesNeurocrine Bio expects $238M in Q4 Ingrezza sales
seekingalpha.com - January 12 at 8:35 PM
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program MilestonesNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
finance.yahoo.com - January 12 at 8:35 PM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Eiry Roberts Sells 2,632 SharesNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Eiry Roberts Sells 2,632 Shares
www.americanbankingnews.com - January 10 at 6:46 PM
AMRX vs. NBIX: Which Stock Is the Better Value Option?AMRX vs. NBIX: Which Stock Is the Better Value Option?
finance.yahoo.com - January 10 at 3:17 PM
Idorsia Pharmaceuticals Ltd: Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsyIdorsia Pharmaceuticals Ltd: Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy
www.finanznachrichten.de - January 10 at 2:38 AM
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric EpilepsyNeurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
www.prnewswire.com - January 10 at 1:57 AM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Buy" from AnalystsNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 10 at 1:50 AM
Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?
finance.yahoo.com - January 9 at 4:36 PM
Why Neurocrine Biosciences Soared 50.5% in 2019Why Neurocrine Biosciences Soared 50.5% in 2019
www.fool.com - January 7 at 10:12 PM
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference  Live Audio Webcast will be on January 13, 2020Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020
finance.yahoo.com - January 6 at 7:28 PM
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Fair?Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Fair?
finance.yahoo.com - January 6 at 2:28 PM
 Brokerages Expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Will Announce Quarterly Sales of $220.48 Million Brokerages Expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Will Announce Quarterly Sales of $220.48 Million
www.americanbankingnews.com - January 4 at 5:32 AM
 Analysts Anticipate Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to Post $0.73 Earnings Per Share Analysts Anticipate Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to Post $0.73 Earnings Per Share
www.americanbankingnews.com - January 2 at 6:22 AM
How Did Neurocrine Biosciences, Inc. (NBIX) Compare Against Top Hedge Fund Stocks in 2019?How Did Neurocrine Biosciences, Inc. (NBIX) Compare Against Top Hedge Fund Stocks in 2019?
finance.yahoo.com - December 25 at 6:03 PM
S&P Rises for Fourth Straight WeekS&P Rises for Fourth Straight Week
finance.yahoo.com - December 23 at 12:24 PM
Commit To Purchase Neurocrine Biosciences At $85, Earn 4.9% Using OptionsCommit To Purchase Neurocrine Biosciences At $85, Earn 4.9% Using Options
www.nasdaq.com - December 12 at 1:01 PM
Aurelius bearish on Neurocrine BiosciencesAurelius bearish on Neurocrine Biosciences
seekingalpha.com - December 11 at 2:26 PM
With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Is InterestingWith EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Is Interesting
finance.yahoo.com - December 6 at 1:43 PM
Hedge Funds Have Never Been This Bullish On Neurocrine Biosciences, Inc. (NBIX)Hedge Funds Have Never Been This Bullish On Neurocrine Biosciences, Inc. (NBIX)
finance.yahoo.com - November 27 at 7:59 AM
Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx ConferenceNeurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference
www.marketwatch.com - November 26 at 4:19 PM
Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive DyskinesiaNeurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia
finance.yahoo.com - November 12 at 6:27 PM
Edited Transcript of NBIX earnings conference call or presentation 4-Nov-19 9:30pm GMTEdited Transcript of NBIX earnings conference call or presentation 4-Nov-19 9:30pm GMT
finance.yahoo.com - November 8 at 10:13 PM
BRIEF-Neurocrine Biosciences Announces Third Quarter ResultsBRIEF-Neurocrine Biosciences Announces Third Quarter Results
www.msn.com - November 5 at 7:51 PM
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2019 Results - Earnings Call TranscriptNeurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - November 5 at 3:16 AM
Neurocrine Biosciences Inc (NBIX) Q3 2019 Earnings Call TranscriptNeurocrine Biosciences Inc (NBIX) Q3 2019 Earnings Call Transcript
www.nasdaq.com - November 4 at 11:45 PM
Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue EstimatesNeurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates
finance.yahoo.com - November 4 at 11:45 PM
Neurocrine Biosciences Inc Reveals Rise In Q3 EarningsNeurocrine Biosciences Inc Reveals Rise In Q3 Earnings
www.nasdaq.com - November 4 at 6:44 PM
Neurocrine Biosciences EPS misses by $0.09, beats on revenueNeurocrine Biosciences EPS misses by $0.09, beats on revenue
seekingalpha.com - November 4 at 6:44 PM
Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment?
finance.yahoo.com - November 4 at 6:44 PM
Neurocrine Biosciences Reports Third Quarter 2019 Financial ResultsNeurocrine Biosciences Reports Third Quarter 2019 Financial Results
finance.yahoo.com - November 4 at 6:44 PM
Neurocrine Biosciences, Inc. Common Stock (NBIX) Earnings Report DateNeurocrine Biosciences, Inc. Common Stock (NBIX) Earnings Report Date
www.nasdaq.com - November 3 at 11:21 PM
Neurocrine Biosciences Q3 2019 Earnings PreviewNeurocrine Biosciences Q3 2019 Earnings Preview
seekingalpha.com - November 3 at 11:21 PM
Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)
finance.yahoo.com - November 1 at 1:32 PM
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings GrowthNeurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
finance.yahoo.com - October 28 at 12:31 PM
Were Hedge Funds Right About Piling Into Neurocrine Biosciences (NBIX)?Were Hedge Funds Right About Piling Into Neurocrine Biosciences (NBIX)?
finance.yahoo.com - October 22 at 7:07 PM
Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4
finance.yahoo.com - October 15 at 1:23 PM
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial ResultsNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
www.marketwatch.com - October 14 at 5:58 PM
Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?
finance.yahoo.com - October 14 at 12:57 PM
Neurocrine Biosciences Presents New Data Analyses...Neurocrine Biosciences Presents New Data Analyses...
www.benzinga.com - October 4 at 10:22 PM
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych CongressNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
www.prnewswire.com - October 4 at 7:55 PM
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych CongressNeurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
finance.yahoo.com - October 1 at 4:31 PM
Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs OfficerNeurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer
finance.yahoo.com - September 30 at 8:11 PM
Investors Who Bought Neurocrine Biosciences (NASDAQ:NBIX) Shares Five Years Ago Are Now Up 476%Investors Who Bought Neurocrine Biosciences (NASDAQ:NBIX) Shares Five Years Ago Are Now Up 476%
finance.yahoo.com - September 27 at 5:33 PM
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinsons Disease, at the 2019 International Congress of Parkinsons Disease and Movement Disorders®Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
finance.yahoo.com - September 17 at 8:05 PM
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Neutral Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel